StreetSmart Live! Presents Frank Holmes’ Virtual Junior Mining Expo on 11/12/2020. Learn More

Get the Latest Investment Ideas Delivered Straight to Your Inbox.

News Update

TICKERS: RVV; RVVTF

Biotech Expects Interim Analysis Data from Phase 3 COVID-19 Study by Year-End
News Update

Share on Stocktwits

Source:

Revive Therapeutics anticipates that more than 200 patients will complete its Phase 3 clinical trial of Bucillamine in patients with mild-moderate COVID-19 by the end of December 2020 and stated that those results will help identify the best dosage levels for the rest of the trial.

In a news release, Revive Therapeutics Ltd. (RVV:TSX.V; RVVTF:OTCMKTS) provided an update on its U.S. Food & Drug Administration (FDA) approved Phase 3 clinical study of Bucillamine in patients with mild-moderate COVID-19. The company indicated that it plans to conduct the trial at 10 locations across five U.S. states.

The firm projects that more than 200 patients will finish the trial by the end of December of this year. The company stated that the results obtained will be complied and reviewed in the interim analysis that will be instrumental in selecting the best performing Bucillamine dose arm for the remainder of the trial as well as for future expanded studies in much more severe COVID-19 cases.

The company's CEO Michael Frank commented, "We are one of a few life sciences companies evaluating an investigational drug in a Phase 3 clinical trial for COVID-19 and with the rising prevalence of cases throughout the U.S., we are confident that our targets will be achieved to support the potential FDA approval and commercialization of Bucillamine for the treatment of the virus."

The firm noted that a recent publication indicated that N-acetyl-cysteine (NAC) demonstrated some potential in COVID-19 treatment. The company stated that Bucillamine has a well-established 30-year safety record in use in rheumatoid arthritis treatment and has been has been shown to be 16 times more potent as a thiol donor in vivo than NAC.

The company stated it plans to enroll up to 1,000 patients in total in its Phase 3 multi-center double-blind clinical trial of Bucillamine in patients with mild to moderate COVID-19. Patients in the study will be randomized to receive either 100 mg or 200 mg of Bucillamine or placebo three times per day for 14 days. The firm advised that the study's primary objective is to compare the frequency of hospitalization or death in patients with mild-moderate COVID-19 receiving Bucillamine therapy versus those receiving a placebo.

The company advised that an independent data and safety monitoring board (DSMB) will perform an interim analysis after 210 patients have been treated and followed up for 28 days after randomization. After that period, the dosage level which demonstrated the best results will be chosen and randomized at a 2:1 ratio versus placebo. The DSMB will closely monitor the data and will perform additional interim analyses after 400, 600, and 800 patients complete their respective 28-day treatments. The firm mentioned that it now projects that the first round of over 200 patients will complete the study prior to the end of December 2020.

Revive Therapeutics stated that it is not making claims of any kind that its product has the ability to cure or eliminate COVID-19 (SARS-2 Coronavirus) at this time.

[NLINSERT]

Disclosure:
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: Revive Therapeutics. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the decision to publish an article until three business days after the publication of the article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Revive Therapeutics, a company mentioned in this article.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.




Want to read more about Biotechnology / Pharmaceuticals investment ideas?
Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe